We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+2.35%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$7.71B
AUM Growth
-$201M
Cap. Flow
-$473M
Cap. Flow %
-6.14%
Top 10 Hldgs %
39.08%
Holding
169
New
28
Increased
15
Reduced
34
Closed
19

Top Buys

Rank Stock Value
1
NAUT icon
Nautilus Biotechnolgy
NAUT
+$96.5M
2
UTHR icon
United Therapeutics
UTHR
+$84.1M
3
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$79.6M
4
ZY
Zymergen Inc. Common Stock
ZY
+$64.5M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$60M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.3M
2
ALLO icon
Allogene Therapeutics
ALLO
+$40.4M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$39.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$36.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$35.4M

Sector Composition

Rank Sector Weight
1 Healthcare 87.76%
2 Miscellaneous 11.22%
3 Financials 0.64%
4 Consumer Staples 0.2%
5 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVRX icon
101
CVRx
CVRX
$79.9M
$12.3M 0.16%
+440,000
New +$12.3M
BLSA
102
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$10.5M 0.14%
1,000,000
– –
CTMX icon
103
CytomX Therapeutics
CTMX
$586M
$10.4M 0.13%
1,640,957
-513,017
-24% -$3.99M
RACB
104
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$10.1M 0.13%
1,000,000
– –
SMIHU
105
DELISTED
Summit Healthcare Acquisition Corp. Units
SMIHU
$10M 0.13%
+1,000,000
New +$10M
TBIO
106
DELISTED
Telesis Bio, Inc. Common Stock
TBIO
$9.35M 0.12%
+23,611
New +$8.35M
CNCE
107
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$9.07M 0.12%
2,150,641
– –
FDMT icon
108
4D Molecular Therapeutics
FDMT
$753M
$9.04M 0.12%
375,256
-69,622
-16% -$2.13M
PRVB
109
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$8M 0.1%
948,481
-1,903,577
-67% -$15.4M
PSTX
110
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$7.89M 0.1%
787,745
– –
ACHL
111
DELISTED
Achilles Therapeutics
ACHL
$7.39M 0.1%
755,375
– –
SILK
112
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$7.04M 0.09%
147,133
-192,967
-57% -$9.83M
DRIO icon
113
DarioHealth
DRIO
$66.1M
$7M 0.09%
16,393
– –
TSHA icon
114
Taysha Gene Therapies
TSHA
$1.65B
$6.79M 0.09%
320,440
-150,000
-32% -$3.46M
PRVA icon
115
Privia Health
PRVA
$2.6B
$5.99M 0.08%
+135,000
New +$4.98M
AKYA
116
DELISTED
Akoya BioSciences
AKYA
$5.8M 0.08%
+300,000
New +$6.19M
TNGX icon
117
Tango Therapeutics
TNGX
$4.03B
$5.69M 0.07%
500,000
– –
MREO
118
Mereo BioPharma
MREO
$45.5M
$5.38M 0.07%
1,696,068
-4,303,932
-72% -$14.4M
CHFW.U
119
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$5.2M 0.07%
500,000
– –
PRTA icon
120
Prothena Corp
PRTA
$428M
$5.14M 0.07%
+100,000
New +$3.12M
LGV.U
121
DELISTED
Longview Acquisition Corp. II Units, each consisting of one share of Class A Common Stock and one-fifth of one redeemable Warrant
LGV.U
$5.04M 0.07%
500,000
– –
OBIO icon
122
Orchestra BioMed
OBIO
$363M
$4.59M 0.06%
450,000
– –
TARA icon
123
Protara Therapeutics
TARA
$222M
$4.11M 0.05%
421,641
-1
-0% -$11
MRUS
124
DELISTED
Merus
MRUS
$3.69M 0.05%
175,000
– –
AMWL icon
125
American Well
AMWL
$233M
$3.65M 0.05%
14,500
-3,250
-18% -$937K
3 4
5
6 7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Perceptive Advisors held 169 positions worth $7.71B, down 2.5% from $7.91B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Perceptive Advisors withdrew a net $473M in Q2 2021, closing 19 positions and reducing 34 holdings. Its most notable exit was Allogene Therapeutics, an estimated $40.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Nautilus Biotechnolgy worth $90M.

  • Perceptive Advisors's largest Q2 2021 buy was Nautilus Biotechnolgy: 8,911,151 shares worth $90M.
  • Perceptive Advisors added most to United Therapeutics in Q2 2021, an estimated $84.1M increase.
  • Perceptive Advisors's biggest Q2 2021 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $46.3M.
  • Perceptive Advisors fully exited Allogene Therapeutics in Q2 2021, selling an estimated $40.4M.
  • Perceptive Advisors's ten largest holdings make up 39% of its $7.71B portfolio in Q2 2021.
  • Perceptive Advisors opened 28 new positions and closed 19 in Q2 2021.
  • Perceptive Advisors's portfolio value fell 2.5% quarter-over-quarter to $7.71B.

Based on Perceptive Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.